Trial Profile
A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Doxycycline (Primary)
- Indications Exanthema
- Focus Adverse reactions
- Sponsors Foamix; VYNE Therapeutics
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 31 May 2016 Results published in a Foamix Pharmaceuticals media release.
- 31 May 2016 Data will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Foamix Pharmaceuticals media release.